Aditxt Signs Agreement to Acquire Appili Therapeutics

Seeking AlphaApr 2 08:51 ET

Appili Therapeutics Reports Q3 Results

Seeking AlphaFeb 14 08:37 ET

Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan

Appili Therapeutics Inc. (APLI.TO) on Friday said the United States Patent and Trademark Office (USPTO) has published patent claims for ATI-1701. The patent covers the composition and preparation methods for the vaccine through 2039.

MT NewswiresDec 15, 2023 08:18 ET

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension

FDA approves LIKMEZ as the brand name for Metronidazole Oral Suspension (LIKMEZ is a Trademark of Saptalis Pharmaceuticals, LLC) Currently LIKMEZ is the only liquid oral suspension of metronidazole approved in the

BusinesswireSep 25, 2023 07:54 ET

Appili Therapeutics GAAP EPS of -C$0.01

Seeking AlphaAug 11, 2023 17:45 ET

Press Release: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.

Dow JonesAug 11, 2023 16:50 ET